Edition:
India

Chiasma Inc (CHMA.OQ)

CHMA.OQ on NASDAQ Stock Exchange Global Select Market

3.72USD
10:03pm IST
Change (% chg)

$-0.09 (-2.23%)
Prev Close
$3.81
Open
$3.76
Day's High
$3.80
Day's Low
$3.71
Volume
23,290
Avg. Vol
203,276
52-wk High
$7.75
52-wk Low
$2.90

Latest Key Developments (Source: Significant Developments)

Chiasma Announces Planned Transition Of Former CEO
Thursday, 1 Oct 2020 

Oct 1 (Reuters) - Chiasma Inc ::CHIASMA ANNOUNCES PLANNED TRANSITION OF FORMER CEO.CHIASMA INC - MARK FITZPATRICK INTENDS TO STEP DOWN AS PRESIDENT AND PRINCIPAL FINANCIAL OFFICER.CHIASMA INC - PLANS TO INITIATE EXECUTIVE SEARCH TO IDENTIFY FITZPATRICK'S SUCCESSOR.CHIASMA INC - FITZPATRICK HAS AGREED TO REMAIN IN HIS CURRENT POSITION UNTIL JUNE 30, 2021 OR COMPANY'S APPOINTMENT OF ITS NEXT CFO, IF EARLIER.  Full Article

Chiasma Reports Q2 Loss Per Share $0.50
Tuesday, 11 Aug 2020 

Aug 10 (Reuters) - Chiasma Inc ::CHIASMA REPORTS SECOND QUARTER 2020 RESULTS AND SIGNIFICANT PROGRESS ON LAUNCH PREPAREDNESS.Q2 LOSS PER SHARE $0.50.Q2 EARNINGS PER SHARE ESTIMATE $-0.38 -- REFINITIV IBES DATA.  Full Article

Chiasma Announces Data From Open-Label Extension Study Of Chiasma Optimal Phase 3 Trial Evaluating Mycapssa
Tuesday, 28 Jul 2020 

July 27 (Reuters) - Chiasma Inc ::CHIASMA ANNOUNCES 48-WEEK SAFETY AND EFFICACY DATA FROM THE OPEN-LABEL EXTENSION STUDY OF ITS CHIASMA OPTIMAL PHASE 3 TRIAL EVALUATING MYCAPSSA® IN PATIENTS WITH ACROMEGALY.CHIASMA INC - ALL MYCAPSSA RESPONDERS (IGF-1 WITHIN NORMAL LIMITS) WHO ENROLLED INTO OLE COMPLETED 48-WEEK PERIOD.CHIASMA INC - SAFETY PROFILE OBSERVED DURING OLE WAS GENERALLY CONSISTENT WITH SAFETY OF MYCAPSSA NOTED IN 36-WEEK CHIASMA OPTIMAL TRIAL.  Full Article

Chiasma Inc Files For Common Stock Offering Of Up To $60 Mln
Wednesday, 8 Apr 2020 

April 8 (Reuters) - Chiasma Inc ::CHIASMA INC FILES FOR COMMON STOCK OFFERING OF UP TO $60.0 MILLION - SEC FILING.  Full Article

Chiasma Enters Into Revenue Interest Financing Agreement For Up To $75 Mln With Healthcare Royalty Partners
Wednesday, 8 Apr 2020 

April 8 (Reuters) - Chiasma Inc ::CHIASMA ENTERS INTO REVENUE INTEREST FINANCING AGREEMENT FOR UP TO $75 MILLION WITH HEALTHCARE ROYALTY PARTNERS.CHIASMA INC - UNDER TERMS OF AGREEMENT, CHIASMA WILL RECEIVE $25 MILLION FROM HCR ON APRIL 14.CHIASMA INC - IS ENTITLED TO RECEIVE AN ADDITIONAL $25 MILLION UPON U.S. FDA APPROVAL OF MYCAPSSA.CHIASMA - ENTITLED TO GET ADDITIONAL $15 MILLION UPON AVAILABILITY OF COMMERCIAL DRUG SUPPLY AND FIRST COMMERCIAL SALE OF MYCAPSSA.CHIASMA INC - ENTITLED TO RECEIVE AN ADDITIONAL $10 MILLION IN EARLY 2022 SUBJECT TO ACHIEVEMENT OF A COMMERCIAL MILESTONE.CHIASMA INC - HCR WILL RECEIVE A TIERED ROYALTY IN LOW DOUBLE DIGITS ON WORLDWIDE ANNUAL NET REVENUES OF MYCAPSSA AND ANY OTHER FUTURE PRODUCTS.  Full Article

Chiasma Reports Fourth Quarter Financial Results
Tuesday, 17 Mar 2020 

March 16 (Reuters) - Chiasma Inc ::CHIASMA REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.29.Q4 EARNINGS PER SHARE ESTIMATE $-0.24 -- REFINITIV IBES DATA.CHIASMA - EXPECTS CURRENT CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES BALANCE IS SUFFICIENT TO FUND OPERATIONS THROUGH AT LEAST 2020.  Full Article

Chiasma Posts Q3 Loss Per Share Of $0.20
Wednesday, 6 Nov 2019 

Nov 5 (Reuters) - Chiasma Inc ::CHIASMA REPORTS THIRD QUARTER 2019 RESULTS.Q3 LOSS PER SHARE $0.20.Q3 EARNINGS PER SHARE ESTIMATE $-0.21 -- REFINITIV IBES DATA.CHIASMA OPTIMAL TRIAL, CONDUCTED UNDER SPA AND DESIGNED TO SUPPORT FDA APPROVAL, MET PRIMARY AND ALL SECONDARY ENDPOINTS.MYCAPSSA® NDA ON TRACK FOR SUBMISSION BY YEAR-END 2019.MPOWERED(TM) PHASE 3 TRIAL, DESIGNED TO SUPPORT EU APPROVAL, PROGRESSING AS PLANNED WITH TOPLINE DATA EXPECTED IN 2H 2020.  Full Article

Chiasma Files For Mixed Shelf Of Up To $200 Million
Saturday, 7 Sep 2019 

Sept 6 (Reuters) - Chiasma Inc ::CHIASMA FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING.  Full Article

Chiasma Reports Q2 Loss Per Share $0.25
Friday, 9 Aug 2019 

Aug 8 (Reuters) - Chiasma Inc ::CHIASMA REPORTS SECOND QUARTER 2019 RESULTS.Q2 LOSS PER SHARE $0.25.Q2 EARNINGS PER SHARE ESTIMATE $-0.29 -- REFINITIV IBES DATA.  Full Article

Chiasma Announces Proposed Offering Of Common Stock
Friday, 26 Jul 2019 

July 25 (Reuters) - Chiasma Inc ::CHIASMA ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.CHIASMA INC - INTENDS TO USE NET PROCEEDS FROM OFFERING PRIMARILY FOR COMMERCIALIZATION OF MYCAPSSA IN UNITED STATES, IF APPROVED.  Full Article

BRIEF-Chiasma Announces Pricing Of A Public Offering Of $70 Mln Of Common Stock And Pre-Funded Warrants

* CHIASMA ANNOUNCES PRICING OF A PUBLIC OFFERING OF $70 MILLION OF COMMON STOCK AND PRE-FUNDED WARRANTS